PMDA drug package insert
ナラトリプタン錠2.5mg「KO」
PMDA Prescription drug · 寿製薬株式会社 · package insert May 26, 2025
Key facts
| Brand names | ナラトリプタン錠2.5mg「KO」 |
|---|---|
| Nonproprietary names | ナラトリプタン塩酸塩 |
| Companies | 製造販売元／寿製薬株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 5-HT1B/1D受容体作動型片頭痛治療剤 |
| Therapeutic category codes | 87216 |
| YJ codes | 2160007F1039 |
| Approval numbers | 30200AMX00158000 |
| Package insert edition | 第2版 |
| Package insert date | May 26, 2025 |
| PMDA document key | 270139_2160007F1039_1 |
| PMDA company code | 270139 |
At a glance
- 1–9 Package insert revisions
- 1–9 Related PMDA documents
- None Safety communications
- No PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: